The Immunology of Ocular GVHD
Ocular GVHD (oGVHD) begins with transplant immunology, but its effects can become intensely local.
After allogeneic hematopoietic stem cell transplantation, the donor immune system may recognize recipient tissues as foreign. In chronic graft-versus-host disease, immune-mediated inflammation and fibrosis can affect multiple organs, including the skin, mouth, gastrointestinal tract, liver, lungs, fascia, genital tract, and eyes.
When the eye is involved, donor-derived immune activity can contribute to inflammation of the ocular surface, including the cornea and conjunctiva, as well as the eyelids. In addition, fibrosis of the lacrimal gland can contribute to severe dry eye. These mechanisms help explain why oGVHD is not simply a surface irritation problem.
The ocular surface is an immune-active environment. It must defend against pathogens while preserving transparency, comfort, and optical function. In oGVHD, that balance can be disrupted. Inflammatory cells and mediators can damage tissues that support tear production, tear stability, epithelial repair, and surface protection.
The lacrimal gland is a key site. It contributes the aqueous component of the tear film. If the gland becomes inflamed or fibrotic, tear production may decline. That leaves the cornea and conjunctiva more exposed to friction, desiccation, and injury.
The conjunctiva is also important. It helps maintain the ocular surface and supports tear-film function through mucin-producing goblet cells. Inflammatory injury can reduce goblet cell support and contribute to scarring. Conjunctival fibrosis may alter the architecture of the ocular surface and eyelids, making disease harder to control.
The cornea may be affected through tear-film instability, epithelial injury, inflammation, exposure, and altered sensation. Because the cornea is central to both vision and comfort, even small surface changes can have a large impact on daily life.
This interconnected biology is why oGVHD can be difficult to treat and measure. A patient’s symptoms may reflect inflammation, gland dysfunction, tear instability, epithelial damage, nerve involvement, eyelid disease, or several mechanisms at once. One clinical sign rarely captures the whole condition.
For patients and advocates, understanding the immune basis of oGVHD can help explain why symptoms may persist and why transplant history matters in eye care. For clinicians and researchers, it reinforces the need to evaluate oGVHD as a disease process, not only a symptom cluster.
A modern scientific view of oGVHD begins with a simple premise: the eye is a target organ of systemic immune dysregulation after transplant. The ocular surface findings are local, but the disease context is systemic.
This article is for educational purposes only and is not medical advice.
Sources:
- Tappeiner C, Heiligenhaus A, Halter JP, et al. “Challenges and concepts in the diagnosis and management of ocular graft-versus-host disease.” Frontiers in Medicine, 2023.
https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2023.1133381/full - Inamoto Y, Valdés-Sanz N, Ogawa Y, et al. “Ocular Graft-versus-Host Disease after Hematopoietic Cell Transplantation.” Biology of Blood and Marrow Transplantation, 2019.
https://pmc.ncbi.nlm.nih.gov/articles/PMC6362842/ - Jagasia MH, Greinix HT, Arora M, et al. “National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report.” Biology of Blood and Marrow Transplantation, 2015.
https://pmc.ncbi.nlm.nih.gov/articles/PMC4329079/
